Latest & greatest articles for alprazolam

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alprazolam or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alprazolam and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alprazolam

1. Alprazolam for essential tremor. (PubMed)

Alprazolam for essential tremor. Essential tremor (ET) is one of the most common movement disorders. Treatment is based primarily on pharmacological agents. On this basis, although primidone and propranolol are well-established treatments in clinical practice, they could be ineffective in 25% to 55% of patients and can produce serious adverse events (AEs) in a large percentage of individuals. For these reasons, evaluating treatment alternatives for ET may be a worthwhile pursuit. Alprazolam has (...) been suggested as a potentially useful agent for treatment of individuals with ET, but its efficacy and safety are uncertain.PrimaryTo assess the efficacy and safety of alprazolam in the treatment of individuals with ET. SecondaryTo examine effects of alprazolam treatment on the quality of life of people with ET.We carried out a systematic search without language restrictions to identify all relevant trials. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January

Full Text available with Trip Pro

2015 Cochrane

2. Alprazolam

Alprazolam Top results for alprazolam - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for alprazolam The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. Treating depression and anxiety with the benzodiazepine alprazolam: new Cochrane review recommends caution

Treating depression and anxiety with the benzodiazepine alprazolam: new Cochrane review recommends caution Treating depression and anxiety with the benzodiazepine alprazolam: new Cochrane review recommends caution Search National Elf Service Search National Elf Service » » » » Treating depression and anxiety with the benzodiazepine alprazolam: new Cochrane review recommends caution Jul 30 2012 Posted by Antidepressants and psychotherapies are the mainstay for treating depression, but another (...) option is the benzodiazepine drug alprazolam, which is recommended for treating depression when anxiety is also involved. Some doctors prescribe a short course of benzodiazepines to help depressed and anxious patients, but this is not supported by NICE guidance. High-potency tranquillisers like alprazolam are thought to have side-effects including dependence, rebound anxiety, memory impairment, accident-proneness and discontinuation syndrome. A new systematic review from the Cochrane Depression

2012 The Mental Elf

4. Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam

Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03398083 Recruitment Status : Completed First Posted : January 12, 2018 Last

2017 Clinical Trials

5. Efficacy of alprazolam sublingual tablets in the treatment of the acute phase of panic disorders. (PubMed)

Efficacy of alprazolam sublingual tablets in the treatment of the acute phase of panic disorders. Panic disorder affects 2-5% of the general population. In Argentina, one million people would be affected with a 91% rate of psychiatric comorbidity. AIM; To compare efficacy parameters between sublingual (ALP-SL) and conventional (ALP-CT) tablets of alprazolam in the treatment of acute phase of panic disorder with and without agoraphobia.A comparative, multicenter (6 sites), double blind (...) and anticipatory anxiety. RESULTS. Both treatments resulted in statistically significant clinical improvement in all measures. ASEX presented no changes during the study. The average dose of alprazolam for 12 weeks was 1.36 ± 0.70 mg/day (1.39 ± 0.77 ALP-CT and 1.33 ± 0.64 ALP-SL). With ALP-SL, panic attacks were shorter (p < 0.05) with shorter extension (p=0.16) and intensity of anticipatory anxiety (p=0.14). The treatment was well tolerated, there being no differences between both groups.Alprazolam has been

2011 Actas españolas de psiquiatría

6. Alprazolam

Alprazolam Alprazolam Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Alprazolam Alprazolam Aka: Alprazolam , Xanax From Related (...) Chapters II. Pharmacokinetics Half Life: 12-15 hours III. Dosing Dose: 0.25 to 0.5 mg PO bid to tid Maximum Daily Dose: 4 mg IV. Risks Very difficult to wean due to addictive potential Avoid if history V. Equivalent Dosing (for Benzodiazepine Withdrawal) = Dose x10 Phenobarbital = Dose x30 Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Alprazolam." Click on the image (or right click) to open the source website in a new browser

2018 FP Notebook

7. The (lack of) effect of alprazolam on eating behavior in anorexia nervosa: A preliminary report. (PubMed)

The (lack of) effect of alprazolam on eating behavior in anorexia nervosa: A preliminary report. Anxiety is a prominent symptom in anorexia nervosa (AN), and higher pre-meal anxiety has been associated with lower caloric intake. Yet, the causal relationship has not been assessed. We proposed that reducing anxiety with a short acting benzodiazepine would increase caloric intake among individuals with AN.In a randomized, double-blind, placebo controlled cross-over study, we administered (...) alprazolam 0.75 mg to inpatients with AN (n = 17) and assessed caloric intake in a laboratory test meal. Within-subject differences in caloric intake, anxiety, and fatigue were compared between alprazolam and placebo days.Caloric intake did not differ on alprazolam versus placebo (t(15) = 1.72, p = .11). Alprazolam did not reduce anxiety, but was associated with increased fatigue.This study was not able to evaluate the causal role of anxiety in meal intake among individuals with AN, as alprazolam did

2014 The International journal of eating disorders

8. Comparison of alprazolam versus captopril in high blood pressure: a randomized controlled trial. (PubMed)

Comparison of alprazolam versus captopril in high blood pressure: a randomized controlled trial. OBJECTIVE. Anxiety is an important cause of acute blood pressure (BP) elevation. However, the role of anxiolysis in this situation is still controversial. In this study, the relationship of anxiety with BP and the effect of anxiolytic treatment on BP were investigated. METHODS. Emergency department (ED) patients with an initial systolic BP (SBP) ≥ 160 mmHg or diastolic BP (DBP) ≥ 100 mmHg but no end (...) organ damage were approached for inclusion in the study. In those consenting to participate, anxiety levels were measured using the State-Trait Anxiety Index (STAI) and Visual Analog Scale for Anxiety (VAS-A). Patients were randomly assigned to receive oral alprazolam 0.5 mg or captopril 25 mg. BP and anxiety levels were measured at baseline and at 1 and 2 h after administration of the study medication. RESULTS. Of 133 patients meeting inclusion criteria, 53 patients agreed to participate

2011 Blood pressure

9. Fed Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg

Fed Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg Fed Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Fed Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00650299 Recruitment Status : Completed First Posted : April 1, 2008 Last Update Posted : April 1, 2008 Sponsor: Mylan Pharmaceuticals Information provided by: Mylan

2008 Clinical Trials

10. A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2008 Clinical Trials

11. Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect

Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect Srisurapanont M, Boonyanaruthee V Authors' objectives To compare the effectiveness of alprazolam and standard antidepressants in the treatment (...) of depression. Searching MEDLINE was searched up to June 1995 using the following headings and terms: 'depressive disorder-drug therapy', 'alprazolam', 'antidepressants' and 'randomised-controlled trial'. Cross-referencing was used to seek out further studies. Study selection Study designs of evaluations included in the review Double-blind, randomised controlled trials (RCTs), which compared the antidepressant effect of alprazolam to that of a standard antidepressant, were included if they measured

1997 DARE.

12. Alprazolam-induced dose-dependent anorgasmia: case analysis (PubMed)

Alprazolam-induced dose-dependent anorgasmia: case analysis Sexual dysfunctions are associated with multiple medical and psychiatric disorders, as well as pharmacotherapies used to treat these disorders. Although sexual dysfunctions negatively affect both quality of life and treatment adherence, patients infrequently volunteer these symptoms and clinicians do not pose directed questions to determine their presence or severity. This issue is especially important in psychiatric patients, for whom (...) most common psychotropics may cause sexual dysfunctions (antidepressants, antipsychotics, anxiolytics and mood-stabilising agents). There is limited literature addressing benzodiazepines, and alprazolam in particular.To report dose-dependent alprazolam anorgasmia.Case analysis with PubMed literature review.A 30-year-old male psychiatric patient presented with new-onset anorgasmia in the context of asymptomatic generalised anxiety disorder, social anxiety, panic disorder with agoraphobia, obsessive

Full Text available with Trip Pro

2018 BJPsych open

13. The Effect of Sympathetic Antagonists on the Antidepressant Action of Alprazolam (PubMed)

The Effect of Sympathetic Antagonists on the Antidepressant Action of Alprazolam Alprazolam is an anti-anxiety drug shown to be effective in the treatment of depression. In this study, the effect of sympathetic receptor antagonists on alprazolam-induced antidepressant action was studied using a mouse model of forced swimming behavioral despair. The interaction of three sympathetic receptor antagonists with benzodiazepines, which may impact the clinical use of alprazolam, was also studied (...) . Behavioral despair was examined in six groups of albino mice. Drugs were administered intraperitoneally. The control group received only a single dose of 1% Tween 80. The second group received a single dose of alprazolam, and the third group received an antagonist followed by alprazolam. The fourth group was treated with imipramine, and the fifth group received an antagonist followed by imipramine. The sixth group was treated with a single dose of an antagonist alone (atenolol, a β1-selective

Full Text available with Trip Pro

2008 The Libyan journal of medicine

14. Effects of calcium channel blockers on antidepressant action of Alprazolam and Imipramine (PubMed)

Effects of calcium channel blockers on antidepressant action of Alprazolam and Imipramine Alprazolam is effective as an anxiolytic and in the adjunct treatment of depression. In this study, the effects of calcium channel antagonists on the antidepressant action of alprazolam and imipramine were investigated. A forced swimming maze was used to study behavioral despair in albino mice. Mice were divided into nine groups (n = 7 per group). One group received a single dose of 1% Tween 80; two groups (...) each received a single dose of the antidepressant alone (alprazolam or imipramine); two groups each received a single dose of the calcium channel blocker (nifedipine or verapamil); four groups each received a single dose of the calcium channel blocker followed by a single dose of the antidepressant (with same doses used for either in the previous four groups). Drug administration was performed concurrently on the nine groups. Our data confirmed the antidepressant action of alprazolam and imipramine

Full Text available with Trip Pro

2007 The Libyan journal of medicine

15. Differential effects of alprazolam and clonazepam on the immune system and blood vessels of non-stressed and stressed adult male albino rats (PubMed)

Differential effects of alprazolam and clonazepam on the immune system and blood vessels of non-stressed and stressed adult male albino rats Benzodiazepines belongs to one of the most commonly used anxiolytic and anticonvulsant drugs in the world. Full description of toxic effects on different organs is lacking for nearly all the current benzodiazepines. The aim of the current work was to study the immunologic and vascular changes induced by sub-chronic administration of alprazolam (...) and clonazepam in non-stressed and stressed adult male albino rats. Forty-two adult male albino rats were divided into 6 groups (I): (Ia) Negative control rats, (Ib): Positive control rats received distilled water, (II): Stressed rats, (III): Non-stressed rats received daily oral dose of clonazepam (0.5 mg/kg), (IV): Stressed rats received daily oral dose of clonazepam (0.5 mg/kg), (V): Non-stressed rats received daily oral dose of alprazolam (0.3 mg/kg). (VI): Stressed rats received daily oral dose

Full Text available with Trip Pro

2011 Interdisciplinary toxicology

16. The surprising reason behind an early refill of alprazolam

The surprising reason behind an early refill of alprazolam The surprising reason behind an early refill of alprazolam The surprising reason behind an early refill of alprazolam | | October 2, 2015 17 Shares Theresa arrived in a cloud of noise and commotion. She had called after four o’clock the day before, but I hadn’t noticed the new message in my electronic inbox before I left the clinic. Her almost brand new alprazolam bottle and her pain pills were missing, and Theresa was reeling. As she (...) alprazolam. This was endorsed for selected patients at the psychopharmacology courses I had attended in Boston many years ago, but it has now fallen out of fashion. “Well, Theresa, you know these controlled substance agreements you’ve had to sign always say that lost or stolen medications will not be replaced,” I said. “But this has never happened to me before.” Her voice was as shaky as her large, bony hands. “I’ve been on alprazolam for years, what happens if I stop it suddenly? I took my last pill

2015 KevinMD blog

17. Case series: 8 patients exposed to phony alprazolam (Xanax) containing fentanyl and/or etizolam

Case series: 8 patients exposed to phony alprazolam (Xanax) containing fentanyl and/or etizolam Case series: 8 patients exposed to phony alprazolam (Xanax) containing fentanyl and/or etizolam » The Poison Review Case series: 8 patients exposed to phony alprazolam (Xanax) containing fentanyl and/or etizolam August 24, 2016, 11:50 pm Adverse Effects From Counterfeit Alprazolam Tablets. Arens AM et al. Ann Emerg Med 2016 Aug 8 [Epub ahead of print] In March of this year,there were 9 deaths (...) reported in Pinellas County, Florida (the Tampa/St. Petersburg area) associated with fake alprazolam (Xanax) tablets containing fentanyl. Earlier, similar counterfeit pills had been seen around San Francisco and in Monroe County Southern Illinois. This letter, from the University of California-San Francisco and the California Poison Control System describes 8 cases — including 1 cardiac arrest — from that region. An additional victim found at the same location as two of the cases was pronounced dead

2016 The Poison Review blog

18. Staccato® Alprazolam for Inhalation in Panic Disorder

Staccato® Alprazolam for Inhalation in Panic Disorder Staccato Alprazolam Single Dose PK - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Staccato Alprazolam Single Dose PK The safety and scientific (...) are developing Staccato Alprazolam for the acute treatment of panic attacks associated with panic disorder. Condition or disease Intervention/treatment Phase Healthy Drug: Alprazolam thermal aerosol Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 50 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment Official Title: Safety, Tolerability, and Pharmacokinetics of a Single

2007 Clinical Trials

19. Influence of alprazolam premedication on the occurrence of postoperative obstructive apnea. (PubMed)

Influence of alprazolam premedication on the occurrence of postoperative obstructive apnea.

2014 Chest

20. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. (PubMed)

A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. A randomized nonblinded study was performed in three cancer centers to test over a 10-day period the efficacy of (1) a triazolobenzodiazepine, alprazolam, 0.5 mg three times a day and (2) use of a behavioral technique in which patients were trained in progressive muscle relaxation at an initial session with a behavioral psychologist and then asked to listen (...) . Although both treatment arms were effective, patients receiving the drug showed a slightly more rapid decrease in anxiety and greater reduction of depressive symptoms. These findings confirm efficacy of both alprazolam and relaxation to reduce cancer-related anxiety and depression. As safe, inexpensive, and effective interventions, physicians should consider their use in cancer patients experiencing anxiety and depressive symptoms.

1991 Journal of clinical oncology : official journal of the American Society of Clinical Oncology